



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/810,898	03/29/2004	Kazuhiro Ohkouchi	2004_0494	1097
513	7590	05/01/2006	EXAMINER	
WENDEROTH, LIND & PONACK, L.L.P. 2033 K STREET N. W. SUITE 800 WASHINGTON, DC 20006-1021			VENKAT, JYOTHSNA A	
		ART UNIT	PAPER NUMBER	
			1615	

DATE MAILED: 05/01/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/810,898	OHKOUCHI ET AL.	
	Examiner	Art Unit	
	JYOTHSNA A. VENKAT Ph. D	1615	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 19 April 2006.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 12,13 and 33 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 12-13 and 33 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____.
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date <u>4/19/06 and 2/16/0</u> .	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input type="checkbox"/> Other: _____.

DETAILED ACTION

The examiner of this application is changed from James Spear to Jyothsna Venkat.

Receipt is acknowledged of IDS filed on 4/19/06 and 2/16/06 and remarks filed on 2/16/06. Claims 12-13 and 33 are pending in the application and the status of the application is as follows. The rejection of these claims under 102 over WO 98/46215 is withdrawn since the range claimed is not same to that disclosed in the patent.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 12-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 90/46215 ('215).

The instant application is claiming a quickly disintegrating solid preparation comprising:

a. An active ingredient

b. Sugar alcohol or saccharide with a mean particle diameter of 30-300 microns

c. Disintegrating agent (carmellose calcium, carboxymethylstarch sodium, croscarmellose sodium or crosspovidone)

d. Cellulose compound (crystalline cellulose, powder cellulose, low substituted hydroxy propyl cellulose or carmellose)

WO '218 teaches all the claimed ingredients in rapidly dissolving dosage form. See the abstract, see pages 4-5, see pages 7-9 for the active ingredients, and see page 17, lines 13-26 for claimed b. The mean particle taught by the document is within the claimed range. See paragraph bridging pages 17-18 for the various saccharide or sugar alcohols. See page 25 for wicking agent. Some of the agents are the species claimed under c as well as d. See the same page, lines 13-20 for povidone of claimed d. See examples and see specially where the document teaches using both c and d into the compositions.

Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to prepare rapidly dosage forms using all the ingredients of WO document. One of ordinary skill in the art would have reasonable expectation of success that the claimed dosage form with ingredients would also dissolve rapidly since using ingredient c helps in transport moisture into the dosage form, and the use of ingredient b helps in the production of a hard, non-friable, directly compressible and rapidly dissolvable in-mouth dosage form. Absent a showing the criticality of the claimed range of the sugar alcohols, the claims are rendered prima facie obvious over WO document.

Claim 33 is rejected under 35 U.S.C. 103(a) as being unpatentable over WO 90/46215 ('215) as applied to claims 12-13 above, and further in view of U. S. Patent 6,923,988 ('988).

Art Unit: 1615

WO as applied above. The difference is WO document does not teach the claimed active ingredients. However patent '988 teaches solid carriers for improved delivery of active ingredients in pharmaceutical compositions. See the abstarcat, see col.s 4-8 for the active ingredients, see claim 29 for the claimed pioglitazone. Accordingly, it would have been obvious to one of ordinary skill in the art to use the claimed pioglitazone of patent into the compositions of WO document. One of ordinary skill in the art would be motivated to use the specific active ingredient with the reasonable expectation of success that the compositions with the specific active ingredient would dissolve rapidly and also increase the bioavailability of the active ingredient. This is a *prima facie* case of obviousness.


The obviousness-type double patenting rejection of claims 12-13 and 33 over patent 6,740,339 is maintained. Applicants request that this rejection be held in abeyance.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to JYOTHSNA A. VENKAT Ph. D whose telephone number is 571-272-0607. The examiner can normally be reached on Monday-Friday, 10:30-7:30:1st Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, THURMAN K. PAGE can be reached on 571-272-0602. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



JYOTHSNA A VENKAT Ph. D
Primary Examiner
Art Unit 1615
